Reuters logo
a month ago
BRIEF- Astellas Pharma submits supplemental new drug application for mirabegron for use in combination with solifenacin succinate 5 mg
June 30, 2017 / 1:26 AM / a month ago

BRIEF- Astellas Pharma submits supplemental new drug application for mirabegron for use in combination with solifenacin succinate 5 mg

1 Min Read

June 30(Reuters) - Astellas Pharma Inc

* Says it announced the submission of a supplemental new drug application to the U.S. Food and Drug Administration (FDA) seeking approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency

Source text in Japanese:goo.gl/e4tP3b

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below